Title: Pharmacologic hyperstabilisation of the HIV-1 capsid lattice induces capsid failure
Authors: Faysal, KR
Walsh, JC
Renner, N
Marquez, CL
Shah, VB
Tuckwell, AJ
Christie, MP
Parker, MW
Turville, SG
Towers, GJ
James, LC
Jacques, DA
Issue Year: 2024
Publisher eLIFE SCIENCES PUBL LTD
Series ELIFE:
Abstract The HIV-1 capsid has emerged as a tractable target for antiretroviral therapy. Lenacapavir, developed by Gilead Sciences, is the first capsid-targeting drug approved for medical use. Here, we investigate the effect of lenacapavir on HIV capsid stability and uncoating. We employ a single particle approach that simultaneously measures capsid content release and lattice persistence. We demonstrate that lenacapavir's potent antiviral activity is predominantly due to lethal hyperstabilisation of the capsid lattice and resultant loss of compartmentalisation. This study highlights that disrupting capsid metastability is a powerful strategy for the development of novel antivirals.
URI: https://publications.svi.edu.au/publications/9657
Other Identifiers 10.7554/eLife.83605
Publication type Article